SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001610618-24-000050
Filing Date
2024-04-24
Accepted
2024-04-24 16:07:06
Documents
13
Period of Report
2024-04-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets

Document Format Files

Seq Description Document Type Size
1 CIDARA THERAPEUTICS, INC. FORM 8-K cdtx-20240423.htm   iXBRL 8-K 33998
  Complete submission text file 0001610618-24-000050.txt   163564

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20240423.xsd EX-101.SCH 1899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20240423_lab.xml EX-101.LAB 22804
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20240423_pre.xml EX-101.PRE 13048
16 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20240423_htm.xml XML 2829
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 24870595
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)